Pancreatic ductal adenocarcinoma (PDAC) has been a particular focus of basic research for many years, not least because of its consistently poor prognosis. The 5-year survival rate is below 10% in most regions worldwide [1]. Even though these figures have increased significantly over the last few decades, the prognosis remains very poor, especially for older patients with advanced stages of the disease, who make up most cases [2].

Since 1990, the absolute number of new cases of acute and chronic pancreatitis has also been steadily increasing worldwide. Despite improvements in diagnosis and treatment, which have resulted in at least a slight decline in age-adjusted incidence from approximately 38 to 33 per 100,000 inhabitants (1990 to 2021) [3], mortality remains significantly elevated for up to 10 years after an episode of pancreatitis compared to the general population [4]. The pancreatic stroma is a key topic in preclinical studies of pancreatitis. Recent data show that both acute and chronic pancreatitis lead to massive remodeling of the stroma, which includes activation of pancreatic stellate cells, pronounced fibrosis, recruitment of immune cells, and the formation of a proinflammatory microenvironment. Furthermore, it has been shown that remodeling of the pancreatic stroma creates an environment that can promote the development of pancreatic tumors [5,6]. This has led to considerable interest in the influence of the stroma on the pathogenesis of pancreatic diseases.

The tumor microenvironment (TME) is also an essential component in malignant processes as it serves as a host for all malignant and nonmalignant cells that could influence the development, progression, and therapeutic response of the tumor. Thus, the diversity of the TME is formed by tumor cells, fibroblasts, adipocytes, lymphocytes, vessels, dendritic cells, specifically cancer-associated fibroblasts (CAFs), and extracellular matrix, which influence each other and, through their cooperation, determine the biology of the tumor [7,8]. Over the past few years, there has been growing interest in vitamin C and its potential role as a therapeutic adjuvant not only in preclinical research. As the TME is characterized by oxidative stress, hypoxia, and metabolic dysregulation, redox-active molecules such as vitamin C are increasingly coming into focus as potential treatment options because they can directly influence these microenvironmental conditions. In the field of TME, vitamin C has also been shown to have immunomodulatory, epigenetic modifying, and cytotoxic functions [8].

Vitamin C is an organic compound that cannot be synthesized endogenously in humans due to the loss of function of L-gulonolactone oxidase. Its functions at physiological concentrations include the reduction of reactive oxygen species (ROS), participation in cell division processes, and the inhibition of aging processes [9]. It has been shown that vitamin C above physiological concentrations of 0.1 mmol/L [10] selectively attacks and kills cancer cells through a pro-oxidative effect, which functions, among other things, via the formation of ROS [11]. This and much higher concentrations can be easily achieved through intravenous injection of pharmacological ascorbate [12]. Functionally, extracellularly oxidized dehydroascorbate is taken up via glucose transporters (eg, glucose transporter 1) and reduced intracellularly by reduced glutathione back to ascorbic acid, whereby glutathione disulfide is subsequently reduced again by nicotinamide adenine dinucleotide phosphate. The resulting deficiency of reduced glutathione and nicotinamide adenine dinucleotide phosphate deprives tumor cells of their ability to neutralize ROS [13] and results in DNA damage and excessive strain on DNA repair systems [14]. Furthermore, it has been shown that ascorbate prevents hypoxia-inducible factor 1-alpha–dependent gene expression by acting on the active site of hypoxia-inducible factor 1-alpha hydroxylase as an additional mechanism of action [15]. Thus, it counteracts the tumor-typical induced HIF1A stabilization, which usually represents a survival and development advantage for the tumor during malignant progression [16]. Many studies report dose-dependent, tumor-specific cytotoxic effects in relation to PDAC [17-19].

In the case of pancreatitis, the antioxidant effects of vitamin C have recently become a focus of interest. It has been shown that patients with acute pancreatitis develop a vitamin C deficiency in the first 5 days, which correlates with the course of the disease in a dose-dependent manner [20]. However, the therapeutic effect is controversial. Many studies have shown a decrease in markers associated with oxidative stress, such as malondialdehyde, and a shorter length of hospital stay, but no benefit has yet been demonstrated in terms of organ failure or survival rates [21,22]. In addition to its function as an ROS scavenger, vitamin C also has a regenerative effect on other redox systems, activating, for example, the nuclear factor erythroid 2–related factor 2/NQO1/HO-1 signaling pathway, which can also reduce damage to pancreatic tissue by upregulating oxidative stress–inducible genes [21]. Furthermore, it has been shown that vitamin C in therapeutic concentrations can reduce elevated proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6 [23].

The effects of vitamin C in relation to PDAC have already been discussed, summarized, and published in a multifaceted and structured manner at the tumor cell level without the clarified aim of reviewing data on CAFs or additional relevant TME components [12,24,25]. However, there is still no systematic overview of the relationships between stromal and epithelial cells of the pancreas when vitamin C is administered. In addition, in the field of benign and inflammatory pancreatic diseases, which are closely related to tumor development, the literature on models and concentrations of vitamin C is considered very diverse and has so far been comprehensively examined only in very few systematic literature studies [20]. Therefore, this scoping review aims to map the scattered evidence on this topic in a structured manner and identify possible research gaps and connections between various pancreatic diseases.

The question posed in a scoping review should generally be open and exploratory as the purpose of this form of literature review is to gain an overview of the existing literature on a topic. To construct the main question of this scoping review, the population, exposure, and outcome scheme was applied [26]. For the first part of this framework, both the epithelial cells of the pancreas and the surrounding pancreatic stroma were selected as the population in benign/inflammatory and malignant diseases of the pancreas. The selected intervention was vitamin C in physiological and therapeutic doses. Finally, any described influences on the populations included under “population” were considered outcomes.

Therefore, the primary research question resulting from the applied scheme was as follows: which data are available on the influence of vitamin C on pancreatic stromal cells and pancreatic cells in benign/inflammatory and malignant diseases of the pancreas?

To specify this broad topic and capture more precise outcomes, five subordinate questions were identified:

This review protocol is reported according to the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines [27]. The final scoping review will be conducted based on the recommendations of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews), which are consistent with those of the Joanna Briggs Institute [28].

The search strategy is reported based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement for reporting literature searches in systematic reviews, which is in part also applicable for scoping reviews [29]. In general, the search strategy should be both comprehensive and in depth to gain a broad overview of the research field but also to integrate all relevant items. This is also necessary to enable the existing data to be divided into specific categories during the review process. We will not impose any restrictions regarding the year of publication of potential papers to avoid bias in this regard. Therefore, the time span of the included publications refers to database inception up to the month of publication of the review.

First, an initial exploratory search was conducted in PubMed to identify relevant keywords and MeSH (Medical Subject Headings) terms and obtain an overview of the possible number of articles to be included. The terms obtained were then compiled into a search strategy according to the population, intervention, comparator, and outcome scheme, and the main systematic search was conducted in the PubMed, MEDLINE, and Web of Science Core Collection databases. Together, these databases provide a broad representation of the relevant literature. While additional databases may further expand coverage, the selected strategy is expected to capture most of the relevant literature. However, the search was supplemented by screening the reference lists of detected literature reviews and an additional broad search conducted in the Bielefeld Academic Search Engine to identify and include gray literature (Table 1). Rerunning of the database searches will be performed at least every 2 months to avoid missing recently published literature.

After searching the databases, the identified hits will be exported to a suitable literature management program, which in this case will be EndNote (version 2025.2; Clarivate Analytics), and duplicates will be automatically and manually removed. This will be followed by a 2-stage screening process carried out by 2 independent reviewers, whereby a title and abstract review will first be conducted, followed by full-text screening. If the 2 reviewers disagree on the inclusion or exclusion of a hit and this disagreement cannot be resolved through discussion, it will be handled by a third experienced reviewer.

The inclusion criteria are based on the population, exposure, and outcome scheme created for our main research question. Accordingly, studies will be included whose population consists of pancreatic cells in malignant and inflammatory pancreatic diseases. Furthermore, vitamin C must be the subject of the intervention, and the effects of this intervention must have been examined at the cellular level.

The criteria that will lead to the exclusion of an article from the review process are outlined in Table 2.

After excluding irrelevant or incomplete studies, the remaining articles will be included in the analysis. The entire selection process will be documented in a flow diagram in accordance with the PRISMA guidelines (Figure 1).

Extracted data from the included articles will be recorded using a prestandardized Microsoft Excel spreadsheet (version 16.104.1) and then finally evaluated for relevance based on the specified inclusion and exclusion criteria. If necessary, the elements queried in this spreadsheet can be expanded during the screening process.

However, the following elements will be extracted first from the included papers: title, author, year of publication, country, pancreatic disease, study design, model, cell lines used, vitamin C isoform, treatment periods with vitamin C, concentrations of vitamin C used, control, primary outcomes regarding pancreatic cells, primary outcomes regarding stromal cells, methods, and key findings.

Data synthesis will be based on a predefined system of categories derived directly from the research questions. After evaluating the extracted data mentioned above, the included studies will be classified into the following categories: (1) disease (eg, PDAC, acute pancreatitis, and chronic pancreatitis), (2) cell type studied (eg, tumor cells, pancreatic stellate cells, and immune cells), (3) experimental model (eg, 2D cell culture, 3D model, and animal model), (4) type of vitamin C intervention (duration and concentrations), and (5) end points studied (eg, cell viability, apoptosis, ROS levels, and inflammatory markers).

The composition of these categories is variable and can be expanded or reduced depending on the scope of the extracted data. Thus, each study can be assigned to a combination of these categories. On this basis, the analysis will be conducted through frequency analyses (eg, number of studies per disease, cell type, or end point), as well as through the identification of recurring combinations of categories. The results will then be presented in the form of tables and graphical representations. Prism (version 10.6.1; GraphPad Software) will be used for this purpose. This will allow us to visualize which combinations of categories have been frequently or rarely investigated in the literature, thereby enabling us to specifically identify research gaps (Figure 2).

Thematic groups will be formed by summarizing studies with comparable end points and intervention parameters. These groups will also be guided by the research questions established. Chapters based on research question 1 might look as follows: (1) cellular mechanisms influenced by vitamin C in PDAC and (2) cellular mechanisms influenced by vitamin C in inflammatory pancreatic diseases. Consequently, a summary of existing findings can be compiled within the corresponding thematic groups to present the current state of research in this field.

Neither a formal risk-of-bias assessment nor a formal assessment of the strength of the body of evidence will be performed as this is not necessary in accordance with the PRISMA-ScR recommendations [25].